Deciphera Pharmaceuticals Key Executives
This section highlights Deciphera Pharmaceuticals's key executives, including their titles and compensation details.
Find Contacts at Deciphera Pharmaceuticals
(Showing 0 of )
Deciphera Pharmaceuticals Earnings
This section highlights Deciphera Pharmaceuticals's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2023 | 2024-02-06 | $-0.58 | $-0.54 |
| Read Transcript | Q3 | 2023 | 2023-10-30 | $-0.60 | $-0.58 |
| Read Transcript | Q2 | 2023 | 2023-08-09 | $-0.62 | $-0.57 |
| Read Transcript | Q1 | 2023 | 2023-05-07 | N/A | N/A |
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
$25.59
Stock Price
$2.21B
Market Cap
355
Employees
Waltham, MA
Location
Financial Statements
Access annual & quarterly financial statements for Deciphera Pharmaceuticals, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Revenue | $163.36M | $134.04M | $96.15M | $42.09M | $25.00M |
| Cost of Revenue | $3.73M | $8.77M | $2.93M | $225.00K | $830.00K |
| Gross Profit | $159.62M | $125.27M | $93.22M | $41.86M | $24.17M |
| Gross Profit Ratio | 97.70% | 93.46% | 97.00% | 99.47% | 96.68% |
| Research and Development Expenses | $234.12M | $187.82M | $257.04M | $198.97M | $157.61M |
| General and Administrative Expenses | $- | $- | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $136.46M | $120.17M | $136.25M | $114.08M | $68.12M |
| Other Expenses | $- | $- | $- | $- | $- |
| Operating Expenses | $370.58M | $307.99M | $393.29M | $313.05M | $225.73M |
| Cost and Expenses | $374.31M | $316.76M | $396.23M | $313.28M | $225.73M |
| Interest Income | $16.45M | $4.51M | $113.00K | $4.70M | $8.54M |
| Interest Expense | $- | $4.51M | $- | $- | $67.00K |
| Depreciation and Amortization | $2.10M | $2.95M | $3.01M | $7.01M | $8.54M |
| EBITDA | $-208.86M | $-182.72M | $-300.08M | $-264.18M | $-192.19M |
| EBITDA Ratio | -127.85% | -136.32% | -312.10% | -627.71% | -768.76% |
| Operating Income | $-210.96M | $-182.72M | $-300.08M | $-271.19M | $-200.73M |
| Operating Income Ratio | -129.14% | -136.32% | -312.10% | -644.36% | -802.90% |
| Total Other Income Expenses Net | $16.45M | $4.51M | $113.00K | $4.70M | $8.47M |
| Income Before Tax | $-194.51M | $-178.21M | $-299.96M | $-266.49M | $-192.26M |
| Income Before Tax Ratio | -119.07% | -132.96% | -311.98% | -633.19% | -769.02% |
| Income Tax Expense | $431.00K | $722.00K | $-3.13M | $- | $-763.00K |
| Net Income | $-194.94M | $-178.93M | $-296.84M | $-266.49M | $-191.49M |
| Net Income Ratio | -119.34% | -133.49% | -308.73% | -633.19% | -765.97% |
| EPS | $-2.29 | $-2.37 | $-5.11 | $-4.78 | $-4.47 |
| EPS Diluted | $-2.29 | $-2.37 | $-5.11 | $-4.78 | $-4.47 |
| Weighted Average Shares Outstanding | 85.06M | 75.50M | 58.08M | 55.78M | 42.87M |
| Weighted Average Shares Outstanding Diluted | 85.06M | 75.50M | 58.08M | 55.78M | 42.87M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 | June 30, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $45.00M | $48.29M | $43.31M | $38.30M | $33.45M | $36.34M | $35.97M | $32.49M | $29.22M | $24.20M | $23.22M | $23.57M | $25.16M | $19.49M | $15.45M | $7.09M | $62.00K | $- | $- | $25.00M |
| Cost of Revenue | $3.69M | $1.78M | $1.29M | $173.00K | $488.00K | $3.25M | $3.34M | $1.80M | $382.00K | $518.00K | $917.00K | $1.27M | $222.00K | $127.00K | $90.00K | $8.00K | $- | $- | $- | $- |
| Gross Profit | $41.31M | $46.51M | $42.03M | $38.13M | $32.96M | $33.10M | $32.63M | $30.70M | $28.84M | $23.68M | $22.30M | $22.30M | $24.93M | $19.36M | $15.36M | $7.08M | $62.00K | $- | $- | $25.00M |
| Gross Profit Ratio | 91.80% | 96.30% | 97.00% | 99.50% | 98.50% | 91.10% | 90.70% | 94.50% | 98.70% | 97.90% | 96.10% | 94.60% | 99.10% | 99.35% | 99.42% | 99.89% | 100.00% | 0.00% | 0.00% | 100.00% |
| Research and Development Expenses | $57.38M | $58.60M | $62.46M | $58.30M | $54.77M | $48.07M | $47.48M | $44.86M | $47.41M | $74.93M | $66.44M | $59.98M | $55.68M | $52.29M | $49.21M | $46.08M | $51.39M | $46.64M | $40.37M | $34.81M |
| General and Administrative Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $44.38M | $17.98M | $13.16M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-20.64M | $- | $- |
| Selling General and Administrative Expenses | $32.78M | $39.15M | $33.25M | $32.61M | $31.45M | $32.20M | $30.03M | $29.62M | $28.32M | $37.15M | $35.53M | $32.83M | $30.75M | $30.07M | $30.14M | $29.93M | $23.94M | $23.74M | $17.98M | $13.16M |
| Other Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Operating Expenses | $90.16M | $97.75M | $95.72M | $90.91M | $86.21M | $80.26M | $77.51M | $74.48M | $75.73M | $112.08M | $101.97M | $92.81M | $86.43M | $82.36M | $79.36M | $76.01M | $75.32M | $70.37M | $58.35M | $47.98M |
| Cost and Expenses | $93.85M | $99.53M | $97.00M | $91.08M | $86.70M | $83.51M | $80.86M | $76.28M | $76.11M | $112.60M | $102.89M | $94.09M | $86.65M | $82.48M | $79.45M | $76.02M | $75.32M | $70.37M | $58.35M | $47.98M |
| Interest Income | $3.76M | $4.48M | $4.11M | $4.21M | $3.65M | $1.93M | $1.84M | $727.00K | $- | $6.00K | $- | $81.00K | $196.00K | $259.00K | $296.00K | $1.69M | $2.46M | $3.17M | $2.17M | $1.54M |
| Interest Expense | $- | $3.65M | $- | $- | $- | $1.95M | $1.84M | $727.00K | $- | $6.00K | $170.00K | $81.00K | $196.00K | $259.00K | $296.00K | $1.69M | $2.46M | $12.00K | $17.00K | $25.00K |
| Depreciation and Amortization | $1.60M | $456.00K | $465.00K | $571.00K | $608.00K | $601.00K | $742.00K | $820.00K | $783.00K | $780.00K | $759.00K | $743.00K | $732.00K | $695.00K | $666.00K | $484.00K | $460.00K | $445.00K | $169.00K | $112.00K |
| EBITDA | $-47.25M | $-50.78M | $-53.69M | $-52.20M | $-53.26M | $-47.16M | $-44.14M | $-42.97M | $-46.89M | $-88.40M | $-78.91M | $-69.77M | $-60.76M | $-62.05M | $-63.03M | $-66.76M | $-72.35M | $-67.20M | $-56.01M | $-21.32M |
| EBITDA Ratio | -105.00% | -105.15% | -123.95% | -136.29% | -159.24% | -129.76% | -122.70% | -132.23% | -160.46% | -365.31% | -339.83% | -295.98% | -241.54% | -318.41% | -408.02% | -941.57% | -116688.71% | 0.00% | 0.00% | -85.29% |
| Operating Income | $-48.85M | $-51.24M | $-53.69M | $-52.77M | $-53.26M | $-47.16M | $-44.88M | $-43.79M | $-47.67M | $-88.40M | $-79.67M | $-70.51M | $-61.49M | $-63.00M | $-64.00M | $-68.93M | $-75.26M | $-70.37M | $-58.35M | $-22.98M |
| Operating Income Ratio | -108.55% | -106.10% | -123.95% | -137.78% | -159.24% | -129.76% | -124.76% | -134.76% | -163.14% | -365.31% | -343.10% | -299.13% | -244.45% | -323.30% | -414.25% | -972.24% | -121390.32% | 0.00% | 0.00% | -91.90% |
| Total Other Income Expenses Net | $3.76M | $4.48M | $4.11M | $4.21M | $3.65M | $1.95M | $1.84M | $727.00K | $- | $6.00K | $-170.00K | $81.00K | $196.00K | $259.00K | $296.00K | $1.69M | $2.46M | $3.16M | $2.16M | $1.51M |
| Income Before Tax | $-45.08M | $-46.76M | $-49.58M | $-48.56M | $-49.61M | $-45.23M | $-43.04M | $-43.06M | $-46.89M | $-88.40M | $-79.84M | $-70.43M | $-61.30M | $-62.74M | $-63.70M | $-67.24M | $-72.81M | $-67.22M | $-56.20M | $-21.46M |
| Income Before Tax Ratio | -100.19% | -96.82% | -114.47% | -126.78% | -148.33% | -124.46% | -119.65% | -132.52% | -160.46% | -365.29% | -343.83% | -298.79% | -243.67% | -321.97% | -412.33% | -948.39% | -117430.65% | 0.00% | 0.00% | -85.84% |
| Income Tax Expense | $- | $431.00K | $-465.00K | $- | $-608.00K | $700.00K | $-3.68M | $-1.45M | $-783.00K | $6.00K | $- | $- | $- | $259.00K | $296.00K | $1.69M | $2.46M | $2.72M | $2.17M | $1.54M |
| Net Income | $-45.08M | $-47.19M | $-49.58M | $-48.56M | $-49.61M | $-45.94M | $-39.37M | $-41.61M | $-46.11M | $-88.39M | $-79.84M | $-70.43M | $-61.30M | $-62.74M | $-63.70M | $-67.24M | $-72.81M | $-67.22M | $-56.20M | $-21.46M |
| Net Income Ratio | -100.19% | -97.71% | -114.47% | -126.78% | -148.33% | -126.39% | -109.43% | -128.05% | -157.78% | -365.28% | -343.83% | -298.79% | -243.67% | -321.97% | -412.33% | -948.39% | -117430.65% | 0.00% | 0.00% | -85.84% |
| EPS | $-0.52 | $-0.54 | $-0.58 | $-0.57 | $-0.60 | $-0.60 | $-0.50 | $-0.58 | $-0.79 | $-1.51 | $-1.37 | $-1.21 | $-1.06 | $-1.11 | $-1.13 | $-1.20 | $-1.36 | $-1.31 | $-1.28 | $-0.56 |
| EPS Diluted | $-0.52 | $-0.54 | $-0.58 | $-0.57 | $-0.60 | $-0.60 | $-0.50 | $-0.58 | $-0.79 | $-1.51 | $-1.37 | $-1.21 | $-1.06 | $-1.11 | $-1.13 | $-1.20 | $-1.36 | $-1.31 | $-1.28 | $-0.56 |
| Weighted Average Shares Outstanding | 87.39M | 86.70M | 85.79M | 85.02M | 82.68M | 76.44M | 78.21M | 71.77M | 58.62M | 58.49M | 58.11M | 57.99M | 57.75M | 56.39M | 56.39M | 55.92M | 53.57M | 51.26M | 43.80M | 38.20M |
| Weighted Average Shares Outstanding Diluted | 87.39M | 86.70M | 85.79M | 85.02M | 82.68M | 76.44M | 78.21M | 72.13M | 58.62M | 58.49M | 58.11M | 57.99M | 57.75M | 56.39M | 56.39M | 55.92M | 53.57M | 51.26M | 43.80M | 38.20M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $83.51M | $64.74M | $87.06M | $135.90M | $120.32M |
| Short Term Investments | $222.71M | $259.75M | $198.57M | $416.03M | $459.26M |
| Cash and Short Term Investments | $306.22M | $324.49M | $285.63M | $551.93M | $579.58M |
| Net Receivables | $31.95M | $22.43M | $20.59M | $13.90M | $- |
| Inventory | $21.21M | $20.56M | $14.12M | $5.72M | $- |
| Other Current Assets | $21.72M | $25.48M | $18.66M | $12.49M | $13.83M |
| Total Current Assets | $381.10M | $392.96M | $339.01M | $584.03M | $593.41M |
| Property Plant Equipment Net | $37.49M | $43.25M | $45.41M | $45.92M | $27.49M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $46.70M | $14.55M | $41.95M | $9.38M | $1.51M |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $8.28M | $3.28M | $3.11M | $3.10M | $- |
| Total Non-Current Assets | $92.47M | $61.08M | $90.47M | $58.40M | $29.00M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $473.57M | $454.04M | $429.48M | $642.43M | $622.41M |
| Account Payables | $26.48M | $18.61M | $13.13M | $12.31M | $19.57M |
| Short Term Debt | $3.50M | $3.23M | $2.87M | $2.46M | $1.75M |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $68.35M | $- | $79.70M | $- | $- |
| Other Current Liabilities | $1.95M | $64.62M | $1.07M | $55.23M | $38.72M |
| Total Current Liabilities | $100.28M | $86.47M | $96.77M | $69.99M | $60.04M |
| Long Term Debt | $22.38M | $25.88M | $27.99M | $28.76M | $15.90M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- |
| Total Non-Current Liabilities | $22.38M | $25.88M | $27.99M | $28.76M | $15.90M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $122.65M | $112.35M | $124.76M | $98.76M | $75.94M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $805.00K | $676.00K | $585.00K | $576.00K | $516.00K |
| Retained Earnings | $-1.43B | $-1.23B | $-1.05B | $-754.47M | $-487.98M |
| Accumulated Other Comprehensive Income Loss | $577.00K | $-983.00K | $51.00K | $11.00K | $111.00K |
| Other Total Stockholders Equity | $1.78B | $1.58B | $1.36B | $1.30B | $1.03B |
| Total Stockholders Equity | $350.92M | $341.69M | $304.72M | $543.68M | $546.47M |
| Total Equity | $350.92M | $341.69M | $304.72M | $543.68M | $546.47M |
| Total Liabilities and Stockholders Equity | $473.57M | $454.04M | $429.48M | $642.43M | $622.41M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $473.57M | $454.04M | $429.48M | $642.43M | $622.41M |
| Total Investments | $269.41M | $274.30M | $240.52M | $425.41M | $460.77M |
| Total Debt | $25.88M | $29.11M | $30.86M | $31.22M | $17.65M |
| Net Debt | $-57.63M | $-35.63M | $-56.20M | $-104.68M | $-102.67M |
Balance Sheet Charts
| Breakdown | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 | June 30, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $91.23M | $83.51M | $108.09M | $81.39M | $114.64M | $64.74M | $82.54M | $109.70M | $95.33M | $87.06M | $53.19M | $90.95M | $201.65M | $135.90M | $111.15M | $155.45M | $229.65M | $120.32M | $173.71M | $57.24M |
| Short Term Investments | $181.30M | $222.71M | $230.99M | $247.35M | $284.00M | $259.75M | $282.04M | $274.15M | $161.22M | $198.57M | $289.08M | $304.40M | $300.53M | $416.03M | $434.17M | $454.89M | $461.85M | $459.26M | $460.88M | $168.18M |
| Cash and Short Term Investments | $272.53M | $306.22M | $339.07M | $328.74M | $398.63M | $324.49M | $364.58M | $383.85M | $256.55M | $285.63M | $342.27M | $395.35M | $502.18M | $551.93M | $545.33M | $610.34M | $691.50M | $579.58M | $634.60M | $225.42M |
| Net Receivables | $32.68M | $31.95M | $27.55M | $23.20M | $22.44M | $22.43M | $23.28M | $25.85M | $23.15M | $20.59M | $18.05M | $18.61M | $21.82M | $13.90M | $11.81M | $7.38M | $- | $- | $- | $25.00M |
| Inventory | $21.10M | $21.21M | $27.11M | $25.34M | $25.53M | $20.56M | $19.13M | $20.89M | $19.63M | $14.12M | $7.25M | $8.21M | $7.09M | $5.72M | $4.60M | $1.39M | $- | $- | $- | $- |
| Other Current Assets | $23.63M | $21.72M | $23.85M | $27.77M | $29.56M | $25.48M | $13.89M | $17.94M | $20.50M | $18.66M | $17.72M | $14.98M | $15.55M | $12.49M | $9.72M | $13.98M | $11.98M | $13.83M | $7.70M | $6.01M |
| Total Current Assets | $349.94M | $381.10M | $417.58M | $405.05M | $476.16M | $392.96M | $420.88M | $448.53M | $319.83M | $339.01M | $385.29M | $437.14M | $546.63M | $584.03M | $571.46M | $633.09M | $703.48M | $593.41M | $642.29M | $256.43M |
| Property Plant Equipment Net | $36.08M | $37.49M | $39.07M | $40.55M | $41.96M | $43.25M | $44.79M | $46.03M | $43.67M | $45.41M | $45.10M | $44.72M | $45.51M | $45.92M | $47.10M | $29.66M | $27.32M | $27.49M | $5.80M | $2.07M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $34.91M | $46.70M | $37.85M | $60.68M | $27.63M | $14.55M | $7.01M | $9.21M | $18.85M | $41.95M | $49.93M | $55.60M | $3.10M | $9.38M | $38.99M | $21.43M | $- | $1.51M | $1.51M | $1.51M |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $-1 | $8.28M | $3.34M | $3.34M | $3.28M | $3.28M | $3.28M | $3.27M | $3.11M | $3.11M | $3.10M | $3.10M | $- | $3.10M | $2.12M | $2.12M | $2.12M | $- | $- | $- |
| Total Non-Current Assets | $70.99M | $92.47M | $80.26M | $104.57M | $72.86M | $61.08M | $55.07M | $58.51M | $65.63M | $90.47M | $98.12M | $103.42M | $48.61M | $58.40M | $88.21M | $53.22M | $29.45M | $29.00M | $7.31M | $3.58M |
| Other Assets | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $420.93M | $473.57M | $497.84M | $509.62M | $549.02M | $454.04M | $475.95M | $507.04M | $385.46M | $429.48M | $483.42M | $540.57M | $595.25M | $642.43M | $659.67M | $686.30M | $732.93M | $622.41M | $649.60M | $260.01M |
| Account Payables | $19.46M | $26.48M | $21.45M | $18.21M | $19.67M | $18.61M | $12.80M | $16.23M | $17.80M | $13.13M | $13.50M | $14.02M | $11.90M | $12.31M | $10.24M | $12.58M | $11.34M | $19.57M | $14.77M | $13.90M |
| Short Term Debt | $3.57M | $3.50M | $3.44M | $3.37M | $3.30M | $3.23M | $3.17M | $3.10M | $2.93M | $2.87M | $2.66M | $2.60M | $2.54M | $2.46M | $2.01M | $1.42M | $1.50M | $1.75M | $602.00K | $500.00K |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $68.35M | $63.46M | $56.06M | $- | $- | $- | $- | $- | $79.70M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Liabilities | $60.40M | $1.95M | $4.55M | $3.40M | $60.94M | $64.62M | $59.50M | $55.21M | $65.94M | $1.07M | $59.62M | $49.43M | $49.34M | $55.23M | $48.94M | $37.33M | $32.23M | $38.72M | $26.88M | $20.93M |
| Total Current Liabilities | $83.43M | $100.28M | $92.89M | $81.03M | $83.91M | $86.47M | $75.47M | $74.55M | $86.67M | $96.77M | $75.79M | $66.05M | $63.79M | $69.99M | $61.19M | $51.34M | $45.07M | $60.04M | $42.26M | $35.34M |
| Long Term Debt | $21.45M | $22.38M | $23.27M | $24.15M | $25.02M | $25.88M | $26.71M | $27.48M | $27.23M | $27.99M | $27.17M | $27.86M | $28.44M | $28.76M | $29.39M | $15.28M | $15.60M | $15.90M | $1.07M | $1.18M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $718.00K | $616.00K |
| Total Non-Current Liabilities | $21.45M | $22.38M | $23.27M | $24.15M | $25.02M | $25.88M | $26.71M | $27.48M | $27.23M | $27.99M | $27.17M | $27.86M | $28.44M | $28.76M | $29.39M | $15.28M | $15.60M | $15.90M | $1.79M | $1.79M |
| Other Liabilities | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $104.88M | $122.65M | $116.17M | $105.19M | $108.94M | $112.35M | $102.18M | $102.03M | $113.90M | $124.76M | $102.96M | $93.91M | $92.23M | $98.76M | $90.58M | $66.62M | $60.67M | $75.94M | $44.05M | $37.13M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $821.00K | $805.00K | $799.00K | $788.00K | $785.00K | $676.00K | $674.00K | $668.00K | $586.00K | $585.00K | $583.00K | $580.00K | $579.00K | $576.00K | $566.00K | $561.00K | $557.00K | $516.00K | $510.00K | $382.00K |
| Retained Earnings | $-1.47B | $-1.43B | $-1.38B | $-1.33B | $-1.28B | $-1.23B | $-1.19B | $-1.14B | $-1.10B | $-1.05B | $-966.04M | $-886.20M | $-815.77M | $-754.47M | $-691.73M | $-628.03M | $-560.79M | $-487.98M | $-420.76M | $-364.57M |
| Accumulated Other Comprehensive Income Loss | $98.00K | $577.00K | $-896.00K | $-967.00K | $-181.00K | $-983.00K | $-2.04M | $-1.27M | $-563.00K | $51.00K | $165.00K | $26.00K | $43.00K | $11.00K | $39.00K | $-8.00K | $763.00K | $111.00K | $61.00K | $175.00K |
| Other Total Stockholders Equity | $1.79B | $1.78B | $1.76B | $1.74B | $1.72B | $1.58B | $1.56B | $1.55B | $1.37B | $1.36B | $1.35B | $1.33B | $1.32B | $1.30B | $1.26B | $1.25B | $1.23B | $1.03B | $1.03B | $586.89M |
| Total Stockholders Equity | $316.05M | $350.92M | $381.67M | $404.43M | $440.08M | $341.69M | $373.78M | $405.01M | $271.56M | $304.72M | $380.46M | $446.66M | $503.01M | $543.68M | $569.09M | $619.68M | $672.26M | $546.47M | $605.55M | $222.88M |
| Total Equity | $316.05M | $350.92M | $381.67M | $404.43M | $440.08M | $341.69M | $373.78M | $405.01M | $271.56M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Stockholders Equity | $420.93M | $473.57M | $497.84M | $509.62M | $549.02M | $454.04M | $475.95M | $507.04M | $385.46M | $429.48M | $483.42M | $540.57M | $595.25M | $642.43M | $659.67M | $686.30M | $732.93M | $622.41M | $649.60M | $260.01M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $420.93M | $473.57M | $497.84M | $509.62M | $549.02M | $454.04M | $475.95M | $507.04M | $385.46M | $429.48M | $483.42M | $540.57M | $595.25M | $642.43M | $659.67M | $686.30M | $732.93M | $622.41M | $649.60M | $260.01M |
| Total Investments | $216.21M | $269.41M | $268.84M | $308.03M | $311.62M | $274.30M | $289.05M | $283.36M | $180.07M | $240.52M | $339.01M | $360.01M | $303.63M | $425.41M | $473.16M | $476.32M | $461.85M | $460.77M | $462.39M | $169.69M |
| Total Debt | $25.02M | $25.88M | $26.71M | $27.52M | $28.32M | $29.11M | $29.88M | $30.58M | $30.16M | $30.86M | $29.83M | $30.46M | $30.98M | $31.22M | $31.40M | $16.71M | $17.10M | $17.65M | $1.68M | $1.68M |
| Net Debt | $-66.20M | $-57.63M | $-81.38M | $-53.87M | $-86.31M | $-35.63M | $-52.66M | $-79.11M | $-65.17M | $-56.20M | $-23.36M | $-60.49M | $-170.66M | $-104.68M | $-79.75M | $-138.74M | $-212.56M | $-102.67M | $-172.04M | $-55.56M |
Annual Cash Flow
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Net Income | $-194.94M | $-178.93M | $-299.96M | $-266.49M | $-192.26M |
| Depreciation and Amortization | $2.10M | $2.95M | $3.01M | $2.31M | $830.00K |
| Deferred Income Tax | $-7.40M | $- | $1.78M | $-1.62M | $- |
| Stock Based Compensation | $50.60M | $51.94M | $46.08M | $37.14M | $20.41M |
| Change in Working Capital | $-1.54M | $-31.65M | $820.00K | $-13.85M | $25.72M |
| Accounts Receivables | $-9.35M | $-1.78M | $-6.70M | $-13.90M | $- |
| Inventory | $-386.00K | $-7.11M | $-10.15M | $-3.24M | $- |
| Accounts Payables | $7.78M | $5.32M | $833.00K | $-7.53M | $10.86M |
| Other Working Capital | $1.95M | $-28.07M | $16.84M | $10.82M | $14.86M |
| Other Non Cash Items | $4.47M | $2.83M | $7.45M | $2.83M | $-4.00M |
| Net Cash Provided by Operating Activities | $-146.70M | $-152.86M | $-240.82M | $-239.68M | $-149.30M |
| Investments in Property Plant and Equipment | $-778.00K | $-841.00K | $-5.97M | $-5.32M | $-4.93M |
| Acquisitions Net | $-13.33M | $33.47M | $-4.00M | $7.00K | $- |
| Purchases of Investments | $-322.57M | $-322.77M | $-335.38M | $-1.10B | $-817.14M |
| Sales Maturities of Investments | $335.90M | $289.30M | $518.20M | $1.13B | $362.00M |
| Other Investing Activities | $13.33M | $-33.47M | $3.99M | $-1.59M | $-441.00K |
| Net Cash Used for Investing Activities | $12.55M | $-34.31M | $176.85M | $28.46M | $-460.52M |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $149.75M | $163.78M | $8.59M | $226.80M | $432.40M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $152.00M | $164.99M | $14.89M | $226.80M | $436.37M |
| Net Cash Used Provided by Financing Activities | $152.00M | $164.99M | $14.89M | $226.80M | $436.37M |
| Effect of Forex Changes on Cash | $910.00K | $-145.00K | $252.00K | $- | $- |
| Net Change in Cash | $18.77M | $-22.32M | $-48.83M | $15.58M | $-173.44M |
| Cash at End of Period | $83.51M | $64.74M | $87.06M | $135.90M | $120.32M |
| Cash at Beginning of Period | $64.74M | $87.06M | $135.90M | $120.32M | $293.76M |
| Operating Cash Flow | $-146.70M | $-152.86M | $-240.82M | $-239.68M | $-149.30M |
| Capital Expenditure | $-778.00K | $-841.00K | $-5.97M | $-5.32M | $-4.93M |
| Free Cash Flow | $-147.47M | $-153.70M | $-246.79M | $-245.00M | $-154.23M |
Cash Flow Charts
| Breakdown | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 | June 30, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-45.08M | $-47.19M | $-49.58M | $-48.56M | $-49.61M | $-45.94M | $-43.04M | $-43.06M | $-46.89M | $-88.39M | $-79.84M | $-70.43M | $-61.30M | $-62.74M | $-63.70M | $-67.24M | $-72.81M | $-67.22M | $-56.20M | $-21.46M |
| Depreciation and Amortization | $1.60M | $456.00K | $465.00K | $571.00K | $608.00K | $601.00K | $742.00K | $820.00K | $783.00K | $780.00K | $759.00K | $743.00K | $732.00K | $695.00K | $666.00K | $484.00K | $460.00K | $445.00K | $169.00K | $112.00K |
| Deferred Income Tax | $- | $-1.85M | $-2.03M | $-1.95M | $- | $- | $- | $-33.00K | $255.00K | $390.00K | $545.00K | $482.00K | $365.00K | $239.00K | $153.00K | $- | $- | $- | $- | $- |
| Stock Based Compensation | $10.17M | $14.07M | $11.16M | $12.86M | $12.51M | $12.31M | $12.37M | $12.99M | $14.27M | $10.79M | $11.79M | $12.37M | $11.12M | $9.71M | $9.83M | $10.61M | $6.99M | $5.34M | $4.73M | $4.11M |
| Change in Working Capital | $-19.62M | $4.57M | $9.05M | $-2.65M | $-12.50M | $-2.32M | $8.63M | $-17.24M | $-20.72M | $8.34M | $7.89M | $4.03M | $-19.43M | $2.09M | $2.83M | $-5.28M | $-13.48M | $7.32M | $29.08M | $-19.21M |
| Accounts Receivables | $-878.00K | $-4.17M | $-4.49M | $-766.00K | $77.00K | $1.23M | $2.38M | $-2.84M | $-2.56M | $-2.55M | $559.00K | $3.21M | $-7.92M | $-2.08M | $-4.43M | $- | $- | $- | $- | $- |
| Inventory | $-918.00K | $972.00K | $3.53M | $-3.63M | $-1.26M | $-3.36M | $3.17M | $-1.44M | $-5.47M | $-6.88M | $881.00K | $-6.13M | $1.97M | $-786.00K | $-1.66M | $- | $- | $- | $- | $- |
| Accounts Payables | $-6.94M | $4.93M | $3.27M | $-1.42M | $993.00K | $5.57M | $-3.39M | $-1.55M | $4.68M | $-345.00K | $-533.00K | $2.14M | $-433.00K | $2.38M | $-2.85M | $1.46M | $-8.51M | $4.40M | $870.00K | $2.96M |
| Other Working Capital | $-10.88M | $2.83M | $6.74M | $3.17M | $188.00K | $-5.76M | $6.47M | $-11.41M | $-17.38M | $36.21M | $13.96M | $9.60M | $-26.10M | $5.16M | $23.53M | $-6.74M | $-4.97M | $2.92M | $28.21M | $-22.18M |
| Other Non Cash Items | $20.45M | $1.14M | $1.12M | $1.11M | $-464.00K | $184.00K | $469.00K | $1.00M | $954.00K | $1.31M | $5.40M | $1.32M | $1.20M | $1.12M | $1.04M | $584.00K | $-1.53M | $-1.73M | $-973.00K | $-811.00K |
| Net Cash Provided by Operating Activities | $-54.59M | $-28.81M | $-29.81M | $-38.63M | $-49.45M | $-35.16M | $-20.83M | $-45.52M | $-51.35M | $-67.18M | $-54.00M | $-51.97M | $-67.68M | $-49.13M | $-49.34M | $-60.84M | $-80.37M | $-55.83M | $-23.19M | $-37.27M |
| Investments in Property Plant and Equipment | $-146.00K | $-63.00K | $-62.00K | $-293.00K | $-360.00K | $-268.00K | $-573.00K | $-287.00K | $- | $1.11M | $-6.01M | $-432.00K | $-637.00K | $-430.00K | $-1.23M | $-2.98M | $-669.00K | $-1.73M | $-2.97M | $-203.00K |
| Acquisitions Net | $- | $-2.26M | $-41.47M | $-4.65M | $35.05M | $- | $5.50M | $103.91M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $-20.26M | $-59.66M | $-33.78M | $-106.28M | $-122.86M | $-82.17M | $-58.71M | $-181.88M | $- | $-21.66M | $-101.60M | $-180.30M | $-31.82M | $-127.76M | $-150.82M | $-614.65M | $-203.53M | $-198.95M | $-364.43M | $-74.15M |
| Sales Maturities of Investments | $83.04M | $61.92M | $75.25M | $110.93M | $87.81M | $98.46M | $53.21M | $77.98M | $59.65M | $119.51M | $122.05M | $120.28M | $156.37M | $175.25M | $153.87M | $599.89M | $203.12M | $202.36M | $72.59M | $- |
| Other Investing Activities | $62.78M | $2.26M | $41.47M | $4.65M | $-35.05M | $287.00K | $-5.50M | $-103.91M | $- | $-7.00K | $-4.00M | $- | $- | $-977.00K | $7.00K | $-1.00K | $-614.00K | $- | $- | $86.61M |
| Net Cash Used for Investing Activities | $62.63M | $2.20M | $41.40M | $4.36M | $-35.41M | $16.30M | $-6.07M | $-104.19M | $59.65M | $98.95M | $14.44M | $-60.45M | $123.91M | $46.08M | $1.82M | $-17.75M | $-1.69M | $1.68M | $-294.81M | $12.26M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $522.00K | $890.00K | $14.62M | $838.00K | $135.12M | $478.00K | $209.00K | $163.78M | $- | $1.00K | $- | $- | $8.59M | $- | $- | $- | $- | $- | $432.40M | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $522.00K | $890.00K | $15.59M | $838.00K | $134.69M | $478.00K | $209.00K | $164.22M | $83.00K | $1.98M | $1.71M | $1.68M | $9.52M | $27.79M | $3.23M | $4.39M | $191.39M | $761.00K | $434.48M | $19.00K |
| Net Cash Used Provided by Financing Activities | $522.00K | $890.00K | $15.59M | $838.00K | $134.69M | $478.00K | $209.00K | $164.22M | $83.00K | $1.98M | $1.71M | $1.68M | $9.52M | $27.79M | $3.23M | $4.39M | $191.39M | $761.00K | $434.48M | $19.00K |
| Effect of Forex Changes on Cash | $-847.00K | $1.14M | $-493.00K | $184.00K | $79.00K | $579.00K | $-470.00K | $-140.00K | $-114.00K | $120.00K | $94.00K | $37.00K | $1.00K | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $7.72M | $-24.58M | $26.69M | $-33.24M | $49.90M | $-17.80M | $-27.16M | $14.37M | $8.27M | $33.87M | $-37.76M | $-110.70M | $65.75M | $24.74M | $-44.29M | $-74.21M | $109.33M | $-53.39M | $116.47M | $-24.99M |
| Cash at End of Period | $91.23M | $83.51M | $108.09M | $81.39M | $114.64M | $64.74M | $82.54M | $109.70M | $95.33M | $87.06M | $53.19M | $90.95M | $201.65M | $135.90M | $111.15M | $155.45M | $229.65M | $120.32M | $173.71M | $57.24M |
| Cash at Beginning of Period | $83.51M | $108.09M | $81.39M | $114.64M | $64.74M | $82.54M | $109.70M | $95.33M | $87.06M | $53.19M | $90.95M | $201.65M | $135.90M | $111.15M | $155.45M | $229.65M | $120.32M | $173.71M | $57.24M | $82.23M |
| Operating Cash Flow | $-54.59M | $-28.81M | $-29.81M | $-38.63M | $-49.45M | $-35.16M | $-20.83M | $-45.52M | $-51.35M | $-67.18M | $-54.00M | $-51.97M | $-67.68M | $-49.13M | $-49.34M | $-60.84M | $-80.37M | $-55.83M | $-23.19M | $-37.27M |
| Capital Expenditure | $-146.00K | $-63.00K | $-62.00K | $-293.00K | $-360.00K | $-268.00K | $-573.00K | $-287.00K | $- | $1.11M | $-6.01M | $-432.00K | $-637.00K | $-430.00K | $-1.23M | $-2.98M | $-669.00K | $-1.73M | $-2.97M | $-203.00K |
| Free Cash Flow | $-54.73M | $-28.87M | $-29.87M | $-38.92M | $-49.81M | $-35.43M | $-21.40M | $-45.81M | $-51.35M | $-66.07M | $-60.01M | $-52.40M | $-68.32M | $-49.56M | $-50.57M | $-63.83M | $-81.04M | $-57.56M | $-26.16M | $-37.47M |
Deciphera Pharmaceuticals Dividends
Explore Deciphera Pharmaceuticals's dividend history, including dividend yield, payout ratio, and historical payments.
Deciphera Pharmaceuticals News
Read the latest news about Deciphera Pharmaceuticals, including recent articles, headlines, and updates.
U.S. FDA Grants Full Approval of Deciphera's ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT)
OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) announced that the U.S. Food and Drug Administration (FDA) has approved ROMVIMZA™ (vimseltinib), a kinase inhibitor, for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity. The FDA previously granted Fast Track designation and Priority Re.
European Medicines Agency Accepts Deciphera's Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)
OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Ono Pharmaceutical, Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) today announced that the European Medicines Agency (EMA) has accepted the marketing authorization application (MAA) for vimseltinib, a colony stimulating factor 1 receptor (CSF1R), for the treatment of patients with tenosynovial giant cell tumor (TGCT), which is under development by Deciphera Pharmaceuticals, Inc. (“Deciphera”), a wholly-owned subsidiary of.
Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The Lancet
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that results from the Company's MOTION pivotal Phase 3 study of vimseltinib in patients with TGCT are being highlighted in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, Illinois,.
Here's What Key Metrics Tell Us About Deciphera Pharmaceuticals (DCPH) Q1 Earnings
While the top- and bottom-line numbers for Deciphera Pharmaceuticals (DCPH) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
DECIPHERA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Deciphera Pharmaceuticals, Inc. - DCPH
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Deciphera Pharmaceuticals, Inc. (NasdaqGS: DCPH) to ONO Pharmaceutical Co., Ltd. Under the terms of the proposed transaction, shareholders of Deciphera will receive $25.60 in cash for each share of Deciphera that they own. KSF is seeking to determine whether this consideration and the process that led to it ar.
INVESTIGATION: The M&A Class Action Firm Announces An Investigation of Deciphera Pharmaceuticals, Inc. - DCPH
NEW YORK , April 29, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and is investigating Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) , relating to its proposed merger with ONO Pharmaceutical Co., Ltd.
ONO to buy Deciphera Pharmaceuticals at a huge premium
Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) is up a whopping 75% today after ONO Pharmaceutical (TYO: 4528) announced plans of buying it for $2.4 billion. Deciphera Pharmaceuticals stock valued at $25.60 The cash offer values each share of Deciphera Pharmaceuticals at $25.60.
Why Is Deciphera Pharmaceuticals (DCPH) Stock Up 72% Today?
Deciphera Pharmaceuticals (NASDAQ: DCPH ) stock is rising higher on Monday after signing a $2.4 billion acquisition agreement with ONO Pharmaceutical. This deal has ONO Pharmaceutical acquiring Deciphera Pharmaceuticals for $25.60 per share in cash.
Shareholder Alert: Ademi LLP investigates whether Deciphera Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with ONO Pharmaceutical Co.
MILWAUKEE , April 29, 2024 /PRNewswire/ -- Ademi LLP is investigating Deciphera (NASDAQ: DCPH) for possible breaches of fiduciary duty and other violations of law in its transaction with ONO. Click here to learn how to join the https://www.ademilaw.com/case/deciphera-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995.
DCPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Deciphera Pharmaceuticals, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) to ONO Pharmaceutical Co., Ltd. for $25.60 per share in cash is fair to Deciphera shareholders. Halper Sadeh encourages Deciphera shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation co.
Deciphera to be acquired by Japan's Ono in all-cash deal valued at $2.4 billion
Deciphera Pharmaceuticals Inc. DCPH, +3.31% said Monday it has agreed to be acquired by Japan's Ono Pharmaceutical Co. Ltd 4528, +1.34% in an all-cash deal valued at $2.4 billion. Under the terms of the deal, Ono will pay $25.60 per Deciphera share through a tender offer after which it will merge the Waltham, Mass.
Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it has entered into a definitive merger agreement with ONO Pharmaceutical Co., Ltd. (ONO), under which ONO will acquire all outstanding shares of Deciphera common stock for $25.60 per share in cash through a tender offer followed by a merger of.
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
NEW YORK , April 18, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) on behalf of the company's shareholders. The investigation seeks to determine whether Deciphera Pharmaceuticals, Inc.'s directors breached their fiduciary duties in connection with recent corporate actions.
Deciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology Forum
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in a fireside chat at the Stifel 2024 Virtual Targeted Oncology Forum on Tuesday, April 16, 2024 at 11:30 AM ET. A live webcast of the fireside chat will be available on the “Events and Presentatio.
Wall Street Analysts Think Deciphera Pharmaceuticals, Inc. (DCPH) Could Surge 48.49%: Read This Before Placing a Bet
The consensus price target hints at a 48.5% upside potential for Deciphera Pharmaceuticals, Inc. (DCPH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in fireside chats at the following investor conferences: TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024 at 1:30 PM ET in Boston, MA Leerink Partners Global Biopharma Conferen.
Wall Street Analysts Believe Deciphera Pharmaceuticals, Inc. (DCPH) Could Rally 59.63%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 59.6% in Deciphera Pharmaceuticals, Inc. (DCPH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial Results
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced financial results for the fourth quarter and year ended December 31, 2023 and provided a corporate update. “We are proud of the significant progress we made across our company throughout 2023, particularly in our late-stage programs as we continue on.
Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call and Webcast on February 6, 2024
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it will report its fourth quarter and full year 2023 financial results on Tuesday, February 6, 2024. In connection with the earnings release, Deciphera's management team will host a live conference call and webcast at 8:00 AM ET on Tuesday, Febr.
Deciphera Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Thursday, February 8, 2024 at 9:00 AM ET in New York, NY. A live webcast of the fireside chat will be av.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for DCPH.